The history of vaccination against cytomegalovirus

摘要: Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In 1980s, one of strains was shown to be safe and effective renal transplant patients. Then, attention switched glycoprotein gB, which give moderate but transient protection against acquisition virus by women. The identification pp65 tegument protein as principal target cellular immune responses resulted new approaches, particularly DNA, plasmids protect hematogenous stem cell recipients. subsequent discovery pentameric complex that generates most neutralizing antibodies led efforts incorporate into vaccines. At this point, there are many candidate CMV vaccines, including live recombinants, replication-defective virus, DNA plasmids, soluble proteins, peptides, virus-like particles vectored envelope proteins.